Taken together, these findings suggest that ESSENCE is an actionable biomarker and that EGF signaling inhibitor selumetinib and ferroptosis inducer sulfasalazine combination treatment may hold promise for the treatment of CRC patients with high ESSENCE expression. The gene discussed is EGF; the disease is colorectal carcinoma.